This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Epidolex Progresses: Will the Marijuana Drug Market Boom?
by Indrajit Bandyopadhyay
Cannabis (or marijuana) based medical products have the potential to become the next booming industry.
Are Options Traders Betting on a Big Move in Tilray (TLRY) Stock?
by Zacks Equity Research
Investors need to pay close attention to Tilray (TLRY) stock based on the movements in the options market lately.
Tilray, Inc. (TLRY) Stock Moves -1.71%: What You Should Know
by Zacks Equity Research
Tilray, Inc. (TLRY) closed at $29.96 in the latest trading session, marking a -1.71% move from the prior day.
The Zacks Analyst Blog Highlights: Anheuser-Busch, Tilray, Boston Beer, Constellation Brands and Aphria
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Anheuser-Busch, Tilray, Boston Beer, Constellation Brands and Aphria
4 Stocks to Ride on the CBD-Infused Beverage Trend
by Zacks Equity Research
CBD-infused drinks are gaining fast popularity among all age groups, thanks to its many health benefits.
Buy Aurora Cannabis (ACB) Stock Before Earnings, Despite Marijuana Volatility?
by Benjamin Rains
Despite growing sales and wider legalization, many pot stocks have been insanely volatile as Wall Street and investors try to wrap their heads around the marijuana industry. So should you think about buying "cheap" Aurora Cannabis (ACB) Stock before Q4 earnings?
The Tide Is Changing & So Are Our Chances
by Panel Of Zacks Experts
Now that the market is getting a bit of an idea of what???s happening in China and the trade deficit was revised down the market is rising on the news.
Implied Volatility Surging for Tilray (TLRY) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Tilray (TLRY) stock based on the movements in the options market lately.
Canopy Growth (CGC) Earnings After The Bell: How High Can They Go?
by Daniel Laboe
Canopy is the clear leader in the marijuana space with a vastly diversified portfolio of cannabis products along with its STZ partnership.
Tilray (TLRY) Catches Eye: Stock Jumps 8.4%
by Zacks Equity Research
Tilray (TLRY) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
Tilray, Inc. (TLRY) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Tilray, Inc. (TLRY) delivered earnings and revenue surprises of -39.13% and 14.10%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Tumbles on Geopolitical Concerns
by Zacks Equity Research
Wall Street Tumbles on Geopolitical Concerns
Wall Street Wobbles on Turmoil in Hong Kong, Argentina
by Zacks Equity Research
U.S. equity futures struggle for direction ahead of trading on Tuesday after turmoil in Hong Kong and Argentina dent investors' sentiments
Tilray to Report Earnings Today: Will It Top or Flop?
by Tirthankar Chakraborty
From global marijuana legalization to the rapidly increasing use of CBD as a wellness product, all of this should help Tilray witness an uptick in second-quarter revenues.
The Zacks Analyst Blog Highlights: Walmart, Macy's, Cisco Systems, and Tilray
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Walmart, Macy's, Cisco Systems, and Tilray
4 Stocks to Win Big as Earnings Season Winds Down
by Tirthankar Chakraborty
As the second quarter draws to a close this week, we highlight a few high-profile companies that are yet to report.
The Zacks Analyst Blog Highlights: Canopy Growth and Tilray
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Canopy Growth and Tilray
Tilray (TLRY) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on revenue growth and other pipeline updates, when Tilray (TLRY) reports second-quarter 2019 results.
2 Marijuana Stocks to Buy Heading into Q2 Earnings and Beyond
by Mitchell Moore
The marijuana industry is projected to grow at an annual rate of about 17% until it reaches $55.8 billion a year in 2025. The cannabis market has roughly tracked the S&P 500' s expansion in 2019 so far.
Tilray, Inc. (TLRY) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Tilray, Inc. (TLRY) closed at $42.53, marking a +0.57% move from the previous day.
Earnings Preview: Tilray, Inc. (TLRY) Q2 Earnings Expected to Decline
by Zacks Equity Research
Tilray, Inc. (TLRY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tilray, Inc. (TLRY) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Tilray, Inc. (TLRY) closed at $40.76, marking a +0.3% move from the previous day.
Marijuana & Blockchain ETFs: Should You Buy?
by Neena Mishra
Cannabis and blockchain are high-risk, high-reward areas of the market. Should investors consider these ETFs?
Tilray, Inc. (TLRY) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Tilray, Inc. (TLRY) closed the most recent trading day at $42.98, moving +0.02% from the previous trading session.
Tilray, Inc. (TLRY) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Tilray, Inc. (TLRY) closed at $43.41 in the latest trading session, marking a -1.9% move from the prior day.